CIBC World Markets’s Clovis Oncology, Inc. CLVS Stock Holding History

CIBC World Markets’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-131,000	Closed	-$8.34M	–	686
2017 Q1	$8.34M	Buy	+131,000	New	+$7.96M	0.07%	204

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CIBC World Markets's CLVS Position: Q2 2017 in Review

CIBC World Markets sold out of Clovis Oncology, Inc. (CLVS) in Q2 2017, closing a stake of 131,000 shares — an estimated $8.34M sold.

CIBC World Markets first reported a position in CLVS in Q1 2017 and held it in 1 quarter. The position peaked at $8.34M in Q1 2017. 271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

CIBC World Markets reported no remaining Clovis Oncology, Inc. position as of Q2 2017 after selling out during the quarter.
CIBC World Markets sold 131,000 Clovis Oncology, Inc. shares in Q2 2017, an estimated $8.34M.
CIBC World Markets first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 1 quarter.
CIBC World Markets's Clovis Oncology, Inc. position peaked at $8.34M in Q1 2017.
271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on CIBC World Markets's 13F filing for Q2 2017, filed 11 Aug 2017.